⁃ In order to be eligible to participate in this study, an individual will be enrolled if they meet the following criteria:

• Patients must voluntarily sign and date informed consent forms that state his or her willingness to comply with all study procedures and availability for the duration of the study.

• Age 12 years old or older

• Subjects with any documented CD4+ T cell hematologic malignancies. Male and female subjects with CD4+ T-cell hematologic malignancies with either relapsed or refractory disease (including those patients who have undergone a prior transplant (if allogeneic, subjects are eligible if there are no remaining donor cells) and patients with an inadequate response after 4-6 cycles of standard chemotherapy) are eligible. Response criteria for each disease subset will be evaluated based on Standard of Care Guidelines.

• Creatinine clearance of \> 60 ml/min (or otherwise non clinically-significant, per study investigator)

• ALT/AST \< 3 x ULN

• Bilirubin \< 2 x ULN

• Pulmonary Function Test (PFT) with a DLCO of ≥ 60%.

• Adequate echocardiogram with EF of ≥50%

• Adequate venous access for apheresis and no other contraindications for leukapheresis